

# **LUPIN ONCOLOGY INC.**

## **AUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED**

**MARCH 31, 2023**

**5801 Pelican Bay Blvd, Suite 500 Naples,  
FL 34108, USA**

## **Independent Auditor's Report**

**To the Board of Directors of Lupin Oncology  
Inc.  
USA**

### **Report on the Financial Statements**

We have audited the accompanying financial statements of LUPIN ONCOLOGY INC. USA ('the Company') which comprise the Balance Sheet as at March 31, 2023, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information, which are prepared in accordance with the accounting principles generally accepted in India.

These financial statements are "special purpose financial statements" and do not constitute a set of statutory financial statements in accordance with the local laws in which the Company is incorporated and cannot be used for any purpose other than the aforesaid.

### **Management's Responsibility for the Financial Statements**

The Holding Company and Company's Board of Directors are responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India and in particular SA 800 'Special Considerations – Audits of Financial Statements Prepared in Accordance with Special Purpose Frameworks'. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial control system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and its loss, total comprehensive income, the changes in equity and its cash flows for the year ended on that date.

### **Emphasis of Matter**

We draw attention to Note 8 to the financial statements which indicate that the Company has incurred loss during the year. Further, the Company's current liabilities exceeded its current assets as at the balance sheet date. Based on the details in the said note, in our opinion, these conditions do not indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. The financial statements of the Company have been prepared on a going concern basis for the reasons stated in the said Note.

Our opinion is not modified in respect of this matter.

### **Report on Other Legal and Regulatory Requirements**

We report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- (b) In our opinion, proper books of account as required for preparation of these financial statements have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account adjusted for accounting principles generally accepted in India.
- (d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.

### **Other Matter**

This report is issued for the purpose of consolidation of financial statements of the Company's holding Company Lupin Limited, India and to comply with the provisions of Section 129 (3) of the Companies Act, 2013.

**FOR M/S.E.E SITABKHAN & CO.  
CHARTERED ACCOUNTANTS**

**E.E. SITABKHAN  
PROPRIETOR  
M.No : 0-30721  
DATE : 03/05/2023**

**UDIN : 23030721BGVGUE5305**

**LUPIN ONCOLOGY INC.****BALANCE SHEET AS AT MARCH 31, 2023**

		As at 31.03.2023	As at 31.03.2023	As at 31.03.2022	As at 31.03.2022
	Note	\$	₹	\$	₹
<b>ASSETS</b>					
<b>Non Current Assets</b>					
Property, Plant and Equipment		-	-	-	-
Intangible Assets Under Development		6,350,000	481,285,550	6,350,000	481,285,550
		6,350,000	481,285,550	6,350,000	481,285,550
<b>Current Assets</b>					
Financial Assets					
Cash and Cash Equivalents	2	758,639	62,337,367	1,162,293	88,093,673
		758,639	62,337,367	1,162,293	88,093,673
<b>Total</b>		<b>7,108,639</b>	<b>543,622,917</b>	<b>7,512,293</b>	<b>569,379,223</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Equity</b>					
Equity Share Capital	3	15,101,000	1,135,721,705	15,101,000	1,135,721,705
Other Equity		(35,043,193)	(2,814,865,654)	(18,631,946)	(1,403,342,694)
		(19,942,193)	(1,679,143,949)	(3,530,946)	(267,620,989)
<b>Current Liabilities</b>					
Financial Liabilities					
Trade Payables					
- Total outstanding dues of other than Micro Enterprises	4	27,050,832	2,222,766,865	11,043,239	837,000,212
		27,050,832	2,222,766,865	11,043,239	837,000,212
<b>Total</b>		<b>7,108,639</b>	<b>543,622,917</b>	<b>7,512,293</b>	<b>569,379,223</b>

See accompanying notes forming part of financial statement

In terms of our report attached

**For E. E Sitabkhan & Co**  
Chartered Accountants  
Firm Registration No. 110300W

**Esmail Sitabkhan**  
Membership No. 30721  
UDIN:

Place :  
Date :

**For and on behalf of the Board of Directors of  
Lupin Oncology Inc.**

**Vinita Gupta**  
Director

Place :  
Date :

**LUPIN ONCOLOGY INC.****STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023**

		For the Current Year ended 31.03.2023 \$	For the Current Year ended 31.03.2023 ₹	For the Previous Year ended 31.03.2022 \$	For the Previous Year ended 31.03.2022 ₹
	Note				
<b>INCOME:</b>					
Revenue from Operations		-	-	-	-
Other Income		-	-	-	-
<b>Total Income</b>		-	-	-	-
<b>EXPENSES:</b>					
Finance Costs	5	14,601	1,172,490	9,388	697,416
Depreciation and Amortisation Expense		-	-	-	-
Other Expenses	6	16,389,925	1,324,970,229	18,622,558	1,386,491,917
<b>Total Expenses</b>		<b>16,404,526</b>	<b>1,326,142,718</b>	<b>18,631,946</b>	<b>1,387,189,333</b>
<b>Profit / (Loss) before Tax</b>		<b>(16,404,526)</b>	<b>(1,326,142,718)</b>	<b>(18,631,946)</b>	<b>(1,387,189,333)</b>
<b>Tax Expense:</b>					
Current Tax (Net)		6,721	539,710	-	-
Deferred Tax (Net)		-	-	-	-
		<b>6,721</b>	<b>539,710</b>	<b>-</b>	<b>-</b>
<b>Profit / (Loss) for the period</b>		<b>(16,411,247)</b>	<b>(1,326,682,428)</b>	<b>(18,631,946)</b>	<b>(1,387,189,333)</b>
<b>Other Comprehensive Income</b>					
(A)(i) Items that will not be reclassified to profit or loss		-	-	-	-
(ii) Income tax relating to item that will not be reclassified to profit or loss		-	-	-	-
(B)(i) Items that will be reclassified to profit or loss					
a. Exchange differences in translating the financial statements			(84,840,532)		(16,153,361)
(ii) Income tax relating to item that will be reclassified to profit or loss		-	-	-	-
<b>Other Comprehensive Income for the period, net of tax</b>		<b>-</b>	<b>(84,840,532)</b>	<b>-</b>	<b>(16,153,361)</b>
<b>Total Comprehensive Income for the period</b>		<b>(16,411,247)</b>	<b>(1,411,522,959)</b>	<b>(18,631,946)</b>	<b>(1,403,342,694)</b>
<b>Earnings per equity share:</b>					
<b>Basic and Diluted</b>	10	(1.09)	(87.85)	(1.71)	(127.20)
Face Value of Equity Share (in USD)		1		1	
See accompanying notes forming part of financial statement					

In terms of our report attached

**For E. E Sitabkhan & Co**

Chartered Accountants

Firm Registration No. 110300W

**Esmail Sitabkhan**

Membership No. 30721

UDIN:

Place :

Date :

**For and on behalf of the Board of Directors of  
Lupin Oncology Inc.**

**Vinita Gupta**

Director

Place :

Date :

**LUPIN ONCOLOGY INC.****STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2023****(a) Equity share capital**

Particulars	As at March 31, 2023			As at March 31, 2022		
	No. of Shares	Amount in USD	Amount in INR	No. of Shares	Amount in USD	Amount in INR
Balance as at beginning of the reporting year	15,101,000	15,101,000	1,135,721,705	-	-	-
Changes in equity share capital during the year	-	-	-	15,101,000	15,101,000	1,135,721,705
Balance as at end of the reporting year	15,101,000	15,101,000	1,135,721,705	15,101,000	15,101,000	1,135,721,705

**(b) Other equity**

Particulars	Reserves & Surplus ( in USD)	Other Comprehensive Income ( in USD)	Total Other Equity	Reserves & Surplus ( in INR)	Other Comprehensive Income ( in INR)	Total Other Equity
	Retained Earnings	Foreign Currency Translation Reserve		Retained Earnings	Foreign Currency Translation Reserve	
Balance as at March 31, 2021	-	-	-	-	-	-
Profit / (Loss) for the year	(18,631,946)	-	(18,631,946)	(1,387,189,333)	-	(1,387,189,333)
Other comprehensive income for the year	-	-	-	-	(16,153,361)	(16,153,361)
Balance as at March 31, 2022	(18,631,946)	-	(18,631,946)	(1,387,189,333)	(16,153,361)	(1,403,342,694)
Profit / (Loss) for the year	(16,411,247)	-	(16,411,247)	(1,326,682,428)	-	(1,326,682,428)
Other comprehensive income for the year	-	-	-	-	(84,840,532)	(84,840,532)
Balance as at March 31, 2023	(35,043,193)	-	(35,043,193)	(2,713,871,761)	(100,993,893)	(2,814,865,654)

In terms of our report attached

**For E. E Sitabkhan & Co**  
Chartered Accountants  
Firm Registration No. 110300W

**Esmail Sitabkhan**  
Membership No. 30721  
UDIN:

Place :  
Date :

**For and on behalf of the Board of Directors of  
Lupin Oncology Inc.**

**Vinita Gupta**  
Director

Place :  
Date :

**LUPIN ONCOLOGY INC.****STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31,2023**

	For the Current Year ended 31.03.2023 \$	For the Current Year ended 31.03.2023 ₹	For the Previous Year ended 31.03.2022 \$	For the Previous Year ended 31.03.2022 ₹
<b>A. Cash Flow from Operating activities</b>				
Profit / (Loss) before Tax	(16,404,526)	(1,326,142,718)	(18,631,946)	(1,387,189,333)
<b>Operating Loss before Working Capital Changes</b>				
Changes in working capital:				
Adjustments for :				
Trade Payables	16,007,593	1,309,214,919	11,043,239	837,000,212
<b>Cash used in Operations</b>	<b>(396,933)</b>	<b>(16,927,799)</b>	<b>(7,588,707)</b>	<b>(550,189,120)</b>
Direct Taxes paid	(6,721)	(539,710)	-	-
<b>Net Cash Used in Operating Activities</b>	<b>(403,654)</b>	<b>(17,467,509)</b>	<b>(7,588,707)</b>	<b>(550,189,120)</b>
<b>B. Cash Flow from Investing Activities</b>				
Capital expenditure on Intangible Assets Under Development	-	-	(6,350,000)	(481,285,550)
<b>Net Cash Used in Investing Activities</b>	<b>-</b>	<b>-</b>	<b>(6,350,000)</b>	<b>(481,285,550)</b>
<b>C. Cash Flow from Financing Activities</b>				
Issue of Equity Shares	-	-	15,101,000	1,135,721,705
Securities Premium on Issue of Equity Shares	-	-	-	-
<b>Net Cash Generated from Financing Activities</b>	<b>-</b>	<b>-</b>	<b>15,101,000</b>	<b>1,135,721,705</b>
Net increase in Cash and Cash equivalents	(403,654)	(17,467,509)	1,162,293	104,247,035
Impact on account of Foreign Currency Translation	-	(8,288,798)	-	(16,153,361)
Cash and Cash equivalents at the beginning of the period	1,162,293	88,093,673	-	-
<b>Cash and Cash equivalents at the end of the period</b>	<b>758,639</b>	<b>62,337,367</b>	<b>1,162,293</b>	<b>88,093,673</b>

Note :

1) The cash flow statement has been prepared under the "indirect method" as set out in the Indian Accounting Standard 7 (Ind AS-7) "Statement of Cash Flows".

In terms of our report attached

**For E. E Sitabkhan & Co**  
Chartered Accountants  
Firm Registration No. 110300W

**Esmail Sitabkhan**  
Membership No. 30721  
UDIN:

Place :  
Date :

**For and on behalf of the Board of Directors of  
Lupin Oncology Inc.**

**Vinita Gupta**  
Director

Place :  
Date :

## LUPIN ONCOLOGY INC.

### NOTES FORMING PART OF THE FINANCIAL STATEMENTS

#### 1A. Company Overview:

Lupin Oncology Inc., ('the Company') incorporated in State of Delaware on 15<sup>th</sup> March, 2021, is an innovation led Transnational Pharmaceutical Company that would produce, develop and market wide range of branded products pertaining to cancer globally.

The Company is a public limited company incorporated and domiciled in USA. The address of its registered office is 5801 Pelican Bay Blvd, Suite 500 Naples, FL 34108, USA.

#### 1B. Significant Accounting Policies

##### i. Basis of preparation of Financial Statements:

The Financial Statement of the Company have been prepared in all material aspects in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified under section 133 of the Companies Act, 2013 ('the Act') read with Rule 4 of the Companies (Indian Accounting Standards) Rules, 2015 as amended and accounting principles generally accepted in India.

These financial statements are presented in US Dollars (\$) which is the functional currency of the company. For the presentation under IND AS, these financials are converted into Indian Rupees (INR) as per the provisions of IND AS 21 "The Effects of Changes in Foreign Exchange Rates". All the resulting exchange differences are recognized in other comprehensive income and presented with equity as Foreign Currency Translation Reserve.

##### ii. Use of Estimates:

The preparation of the Financial Statements in conformity with Ind AS requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the period. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known/ materialize.

##### iii. Property, Plant and Equipment:

Fixed Assets are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

##### iv. Intangible assets:

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises of its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use.

Expenditure on research and development eligible for capitalisation are carried as Intangible assets under development where such assets are not yet ready for their intended use.

##### v. Foreign Currency Transactions/Translations:

(a) Transactions denominated in foreign currency are recorded at exchange rates prevailing at the date of transaction or at rates that closely approximate the rate at the date of the transaction.

- (b) Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate of the reporting date. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.
- (c) Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous standalone financial statements are recognized in the Statement of Profit and Loss in the period in which they arise.

vi. Financial Instruments

A) Financial Assets

Classification

The Company classifies financial assets as subsequently measured at amortised cost, fair value through other comprehensive income or fair value through profit or loss on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

Initial recognition and measurement

All financial assets (not measured subsequently at fair value through profit or loss) are recognised initially at fair value plus transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the Company commits to purchase or sell the asset.

Equity investments

All equity investments in scope of Ind-AS 109 are measured at fair value. Equity instruments which are held for trading are classified as at FVTPL. For all other equity instruments, the Company decides to classify the same either as at fair value through other comprehensive income (FVTOCI) or FVTPL. The Company makes such election on an instrument-by-instrument basis. The classification is made on initial recognition and is irrevocable.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in other comprehensive income (OCI). There is no recycling of the amounts from OCI to Statement of Profit and Loss, even on sale of such investments.

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the Statement of Profit and Loss.

The Company has elected to continue with the carrying value of all its equity investments as recognized in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either:
  - i) the Company has transferred substantially all the risks and rewards of the asset, or

- ii) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

#### Impairment of financial assets

In accordance with Ind-AS 109, the Company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- i) Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance.
- ii) Trade receivables.  
The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivables which do not contain a significant financing component.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

### B) Financial Liabilities

#### Classification

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities at fair value through profit or loss. Such liabilities, including derivatives that are liabilities, shall be subsequently measured at fair value

#### Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

#### Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term.

Gains or losses on liabilities held for trading are recognised in the Statement of Profit and Loss. Financial liabilities designated upon initial recognition at fair value through profit or loss are designated at the initial

date of recognition, and only if the criteria in Ind-AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains/loss are not subsequently transferred to Statement of Profit and Loss. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognised in the Statement of Profit and Loss. The Company has not designated any financial liability as at fair value through profit or loss.

#### Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the Statement of Profit and Loss.

#### Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

#### vii. Income Tax:

Income Taxes are accounted for in accordance with Indian Accounting Standard 12 on "Income Taxes" (Ind AS 12). Tax expense comprises both current tax and deferred tax. Current tax is measured at the amount expected to be paid or recovered from the tax authorities using applicable tax rates.

Deferred tax assets and liabilities are recognized for future tax consequence attributable to timing difference between taxable income and accounting income that are measured at relevant tax rates. At each Balance Sheet date, the Company reassesses unrealized deferred tax assets, to the extent they become reasonably certain or virtually certain of realization, as the case may be.

#### viii. Provisions, Contingent Liabilities and Contingent Assets:

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

#### ix. Earnings per share:

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the period adjusted for the effects of all dilutive potential equity shares.

### **1C. Recent Accounting Pronouncements:**

Ministry of Corporate Affairs ("MCA") notifies new standard or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. On 31 March 2023, MCA amended the Companies (Indian Accounting Standards) Amendment Rules, 2023, applicable, as below:

#### **Ind AS 1 – Presentation of Financial Statements**

The amendments require companies to disclose their material accounting policies rather than their significant accounting policies. Accounting policy information, together with other information, is material when it can reasonably be expected to influence decisions of primary users of general purpose financial statements.

**Ind AS 12 – Income Taxes**

The amendments clarify how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments narrowed the scope of the recognition exemption in paragraphs 15 and 24 of Ind AS 12 (recognition exemption) so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences.

**Ind AS 8 – Accounting Policies, Changes in Accounting Estimates and Errors**

The amendments will help entities to distinguish between accounting policies and accounting estimates. The definition of a change in accounting estimates has been replaced with a definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty”. Entities develop accounting estimates if accounting policies require items in financial statements to be measured in a way that involves measurement uncertainty.

The Company does not expect this amendment to have any significant impact in its financial statements.

	As at 31.03.2023 \$	As at 31.03.2023 ₹	As at 31.03.2022 \$	As at 31.03.2022 ₹
<b>2. CASH AND CASH EQUIVALENTS</b>				
Cash and Cash Equivalents (as per Ind AS-7 "Statements of Cashflows")				
Bank Balances				
- In Current Account	758,639	62,337,367	1,162,293	88,093,673
<b>Total</b>	<b>758,639</b>	<b>62,337,367</b>	<b>1,162,293</b>	<b>88,093,673</b>

## 3. EQUITY

## a) SHARE CAPITAL

Particulars	As at 31.3.2023			As at 31.3.2022		
	Number of shares	\$	₹	Number of shares	\$	₹
<b>Authorised</b> Equity Shares of \$ 1 each	30,000,000	30,000,000	2,244,747,890	30,000,000	30,000,000	2,244,747,890
<b>Issued, Subscribed &amp; Paid up</b> Equity Shares of \$ 1 each fully paid (15,000,000 of the above shares are held by Lupin Limited, the Holding Company)	15,101,000	15,101,000	1,135,721,705	15,101,000	15,101,000	1,135,721,705
<b>Total</b>	<b>15,101,000</b>	<b>15,101,000</b>	<b>1,135,721,705</b>	<b>15,101,000</b>	<b>15,101,000</b>	<b>1,135,721,705</b>

## b) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31.3.2023			As at 31.3.2022		
	Number of shares	\$	₹	Number of shares	\$	₹
Equity Shares outstanding at the beginning of the year	15,101,000	15,101,000	1,135,721,705	-	-	-
Equity Shares Issued during the year	-	-	-	15,000,000.00	15,000,000.00	1,128,025,000
Equity Shares Issued during the year pursuant to Equity Incentive Plan*	-	-	-	101,000.00	101,000.00	7,696,705.00
Equity Shares outstanding at the end of the year	<b>15,101,000</b>	<b>15,101,000</b>	<b>1,135,721,705</b>	<b>15,101,000</b>	<b>15,101,000</b>	<b>1,135,721,705</b>

\*Of the shares issued during the previous year, 21,210 shares are issued against non cash consideration (against services rendered).

## c) Rights attached to Equity Shares

The Company has only one class of Equity shares having a par value of USD 1 per share. Each holder of Equity share is entitled to one vote per share. In the event of liquidation of the company, the shareholders of Equity shares will be entitled to receive remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion to the number of Equity shares held by the shareholders.

## d) More than 5% shareholding in the Company by each shareholder

Name of Shareholder	As at 31.3.2023		As at 31.3.2022	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Lupin Limited	15,000,000	99.33%	15,000,000	99.33%

## e) Shares reserved for issuance under Equity Incentive Plan

The Company, under its Equity Incentive Plan, has reserved 1,764,706 shares for issuance under Equity Incentive Plan. Of these, in the previous year, the Company has issued 101,000 shares. As on 31st March 2023, 1,663,706 shares are reserved.

	As at 31.03.2023 \$	As at 31.03.2023 ₹	As at 31.03.2022 \$	As at 31.03.2022 ₹
<b>4. TRADE PAYABLES</b>				
- Other than Acceptances				
- Total outstanding dues of Others	27,050,832	2,222,766,865	11,043,239	837,000,212
<b>Total</b>	<b>27,050,832</b>	<b>2,222,766,865</b>	<b>11,043,239</b>	<b>837,000,212</b>

		For the Current Year ended	For the Current Year ended	For the Previous Year ended	For the Previous Year ended
		31.03.2023	31.03.2023	31.03.2022	31.03.2022
		\$	₹	\$	₹
<b>5. FINANCE COSTS</b>					
Bank Charges		14,601	1,172,490	9,388	697,416
<b>Total</b>		<b>14,601</b>	<b>1,172,490</b>	<b>9,388</b>	<b>697,416</b>
<b>6. OTHER EXPENSES</b>					
Clinical and Analytical Charges		16,404,180	1,326,113,135	17,977,470	1,338,569,655
Legal and Professional Charges		(14,255)	(1,142,907)	396,193	29,432,350
Miscellaneous Expenses		-	-	248,895	18,489,912
<b>Total</b>		<b>16,389,925</b>	<b>1,324,970,229</b>	<b>18,622,558</b>	<b>1,386,491,917</b>

7. The audit fee of the company is borne by Lupin Limited (Holding company).
8. The Company has incurred a loss during the year. As on March 31, 2023 the Current Liabilities exceed the Current Assets. But a substantial amount of current liability is to the holding company only. The Company is taking steps to generate revenue and a series of strategic measures which aim to reverse the losses. Further, the Holding company supports the funds necessary for the Company to continue as a going concern. The financial statements have been prepared on the assumption that the Company will continue as a going concern and do not include any adjustments related to this matter.
9. Considering the definitions of reportable business segment and reportable geographical segment contained in Indian Accounting Standard 108 (Ind AS 108) "Operating Segments", the management is of the opinion that there is only one reportable business and geographical segment viz. pharmaceuticals and related products, the results of which are disclosed in the financial statements.
10. **Basic and Diluted earnings per share is calculated as under:**

Particulars	2022-23 (\$)	2022-23 (₹)	2021-22 (\$)	2021-22 (₹)
Net Profit / (Loss) after tax attributable to Equity Shareholders	(16,404,526)	(1,326,142,718)	(18,631,946)	(1,387,189,333)
Weighted average number of equity shares outstanding for the year ended March 31, 2023	15,101,000	15,101,000	10,905,767	10,905,767
Earnings per share - Basic and Diluted	(1.09)	(87.85)	(1.71)	(127.20)

11. **Related party Disclosures:**

- a) Name of Related parties and description of relationship:

**Category I : Company whose control exist:**

- Lupin Limited (Holding Company)

**Category II : Fellow Subsidiaries:**

- Lupin Inc
- Lupin Management Inc

**Category III : Key Management Personnel (KMP):**

- Ms. Vinita Gupta (Director)

- b) Transactions with Related parties: -

Sr No.	Description and Nature of transactions	2022-23 (\$)	2022-23 (₹)	2021-22 (\$)	2021-22 (₹)
1.	Clinical and Analytical charges Lupin Limited	16,404,180	1,326,113,135	17,977,470	1,338,569,655
2.	Legal and Professional charges Lupin Limited Lupin Management Inc	1,233 4	100,805 321	703 -	53,247 -
3.	Purchase of Intangible Assets under development Lupin Limited	-	-	6,350,000	460,692,500
4.	Expenses incurred on behalf of the Company Lupin Inc	291,777	23,430,277	295,314	21,938,298

c) Balance due from / to related parties:

Sr No.	Description and Nature of transactions	2022-23 (\$)	2022-23 (₹)	2021-22 (\$)	2021-22 (₹)
1.	Trade Payables: Lupin Limited	27,126,433	2,228,819,991	10,721,021	812,578,344
2.	Lupin Inc	11,800	969,606	14,949	1,133,030
3.	Lupin Management Inc	87,402	7,181,822	-	-

Related Party relationship is as identified by the Company and relied upon by the Auditors.

Signatures to notes 1 to 11

**For E. E Sitabkhan & Co**  
Chartered Accountants  
Firm Registration No. 110300W

**For and on behalf of the Board of Directors of  
Lupin Oncology Inc.**

**Esmail Sitabkhan**  
Membership No. 30721

**Vinita Gupta**  
Director

Place :  
Date :

Place :  
Date :